The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers

Figures & data

Figure 1. The clinicopathological and prognostic significances of REG4 mRNA expression in breast cancer. According to xiantao (A), UALCAN(B) and TCGA(C) data, REG4 hyper-expression was detectable in breast cancer, compared with normal breast tissue (p < 0.05). The negative relationship between REG4 expression and methylation was analysed in breast cancer using xiantao database (D). Its methylation was lower in breast cancer than normal tissues (E). The correlation between REG4 expression and overall, or recurrence-free survival rate of the patients with breast cancer, even stratified by different clinicopathological parameters (F, p < 0.05). Note: N, normal tissue; T, tumour; S, staging; HR, hazard ratio; *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Table 1. The relationship between REG4 mRNA expression and clinicipathological characteristics of breast cancer by xiantao.

Characteristics	Group	Low expression	High expression	p
Age (years)	≦60	313 (28.9%)	288 (26.6%)	0.133
	>60	228 (21.1%)	254 (23.5%)
T stage	T1	130 (12%)	147 (13.6%)	0.572
	T2	320 (29.6%)	309 (28.6%)
	T3	68 (6.3%)	71 (6.6%)
	T4	20 (1.9%)	15 (1.4%)
N stage	N0	259 (24.3%)	255 (24%)	0.900
	N1	177 (16.6%)	181 (17%)
	N2	54 (5.1%)	62 (5.8%)
	N3	37 (3.5%)	39 (3.7%)
M stage	M0	445 (48.3%)	457 (49.6%)	0.783
	M1	11 (1.2%)	9 (1%)
Pathologic stage	Stage I	90 (8.5%)	91 (8.6%)	0.900
	Stage II	310 (29.2%)	309 (29.2%)
	Stage III	116 (10.9%)	126 (11.9%)
	Stage IV	10 (0.9%)	8 (0.8%)
Histological type	IDC	402 (41.1%)	370 (37.9%)	<0.001
	ILC	76 (7.8%)	129 (13.2%)
PR status	Negative	199 (19.2%)	143 (13.8%)	<0.001
	Indeterminate	2 (0.2%)	2 (0.2%)
	Positive	315 (30.5%)	373 (36.1%)
ER status	Negative	138 (13.3%)	102 (9.9%)	0.012
	Indeterminate	1 (0.1%)	1 (0.1%)
	Positive	378 (36.5%)	415 (40.1%)
PAM50 classification	Normal	19 (1.8%)	21 (1.9%)	<0.001
	Lum A	254 (23.5%)	308 (28.4%)
	Lum B	107 (9.9%)	97 (9%)
	Her2	33 (3%)	49 (4.5%)
	Basal	128 (11.8%)	67 (6.2%)
Progression-free survival	Alive	453 (41.8%)	483 (44.6%)	0.013
	Dead	88 (8.1%)	59 (5.4%)

ILC: infiltrating lobular carcinoma; IDC: infiltrating ductal carcinoma; ER: oestrogen receptor; PR: progesterone receptor.

Table 2. The progression-free survival analysis of breast cancer patients by xiantao.

Characteristics	Total	Univariate analysis		Multivariate analysis
		HR (95% CI)	p	HR (95% CI)	p
Age (≦60 vs > 60years)	1082	1.253 (0.904-1.738)	0.175
T stage (T1-T2 vs T3-4)	1044	4.137 (2.370-7.223)	<0.001	2.185 (1.044-4.572)	0.038
N stage (N0 vs N1-3)	1063	3.265 (1.974-5.398)	<0.001	2.122 (1.036-4.344)	0.040
M stage (M0 vs M1)	922	8.315 (4.829-14.315)	<0.001	4.690 (2.169-10.139)	<0.001
PR status (-vs+)	1029	0.558 (0.400-0.779)	<0.001	0.662 (0.386-1.137)	0.135
ER status (- vs +)	1032	0.622 (0.436-0.887)	0.009	0.676 (0.383-1.193)	0.176
Her2 status (-vs +)	715	1.228 (0.712-2.119)	0.461
Menopause (pre&Peri vs post)	971	1.124 (0.756-1.671)	0.565
Histological type (ILC vs IDC)	977	1.278 (0.799-2.044)	0.306
REG4 expression (low vs high)	1082	0.659 (0.474-0.918)	0.014	0.612 (0.419-0.893)	0.011

ILC: infiltrating lobular carcinoma; IDC: infiltrating ductal carcinoma; CI: confidence interval; HR: hazard ratio; ER: oestrogen receptor; PR: progesterone receptor.

Table 3. The relationship between REG4 mRNA expression and clinicipathological characteristics of cervical cancer by xiantao.

Characteristics	Group	Low expression	High expression	p
Age (years)	≦50	99 (32.4%)	89 (29.1%)	0.291
	>50	54 (17.6%)	64 (20.9%)
T stage	T1	64 (26.3%)	76 (31.3%)	0.001
	T2	26 (10.7%)	46 (18.9%)
	T3	17 (7%)	4 (1.6%)
	T4	7 (2.9%)	3 (1.2%)
N stage	N0	57 (29.2%)	77 (39.5%)	0.478
	N1	30 (15.4%)	31 (15.9%)
M stage	M0	55 (43.3%)	61 (48%)	1.000
	M1	5 (3.9%)	6 (4.7%)
Clinical stage	Stage I	80 (26.8%)	82 (27.4%)	0.754
	Stage II	32 (10.7%)	37 (12.4%)
	Stage III	24 (8%)	22 (7.4%)
	Stage IV	13 (4.3%)	9 (3%)
Histological type	Adenosquamous	17 (5.6%)	36 (11.8%)	0.007
	Squamous cell carcinoma	136 (44.4%)	117 (38.2%)
Histologic grade	G1	9 (3.3%)	10 (3.6%)	0.902
	G2	68 (24.8%)	67 (24.5%)
	G3	56 (20.4%)	63 (23%)
	G4	0 (0%)	1 (0.4%)

Figure 2. The relationship between REG4 mRNA expression and immune infiltration in gynecological cancers. The enrichment of immune cells was explored between low and high expression of REG4 in breast, cervical, endometrial, and ovarian cancers using xiantao. Note: DC, dendritic cell; Treg, regulatory T cell; Tcm, central memory T cells; Tem, effector memory T cell; TFH, follicular helper T cell; NK, natural killer. Tdg, γδ T cells.

Figure 3. The REG4-related signal pathways in gynecological cancers. The top REG4-related genes were screened and classified into the signal pathways of KEGG using xiantao database.

Data availability statement

The datasets generated and analysed in the present study are available from the corresponding author on reasonable request.